Christoffer Rosenblad - Xvivo Perfusion Deputy CEO, CFO
| XVIPF Stock | USD 41.23 0.77 1.83% |
CEO
Mr. Christoffer Rosenblad has served as Chief Financial Officer at Xvivo Perfusion AB since 2012 and was Deputy Chief Executive Officer of the Company since July 17, 2017. Previously, he was Business Controller at Ciba Vision Nordic AB, and before that he held financial positions at LG Electronics. He holds MS degree in Mechanical Engineering from Chalmers Tekniska Hogskola and BS degree in Economics from Goteborgs Universitet. since 2017.
| Age | 48 |
| Tenure | 7 years |
| Phone | 46 3 17 88 21 50 |
| Web | https://www.xvivoperfusion.com |
Xvivo Perfusion Management Efficiency
Xvivo Perfusion's management efficiency ratios could be used to measure how well Xvivo Perfusion manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Jeffrey Frelick | Bone Biologics Corp | 58 | |
| Steven Foster | Tenon Medical | 56 | |
Management Performance
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 |
Xvivo Perfusion AB Leadership Team
Elected by the shareholders, the Xvivo Perfusion's board of directors comprises two types of representatives: Xvivo Perfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xvivo. The board's role is to monitor Xvivo Perfusion's management team and ensure that shareholders' interests are well served. Xvivo Perfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xvivo Perfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jaya Tiwari, VP Affairs | ||
| Magnus Nilsson, Advisor | ||
| Katrin Gisselfalt, Global Director | ||
| Charlotte Walldal, Global director | ||
| Lena BSc, Chief Officer | ||
| Andreas MD, Chief Officer | ||
| Johan Holmstrom, Chief Officer | ||
| Christoffer Rosenblad, Deputy CEO, CFO | ||
| Christer Flon, Mang | ||
| Kristoffer Nordstrom, CFO Relations |
Xvivo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Xvivo Perfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Current Valuation | 536.1 M | |||
| Shares Outstanding | 29.83 M | |||
| Shares Owned By Insiders | 12.25 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Earning | 166.11 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 16.90 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.